Senators questioned Novo Nordisk CEO Lars Jørgensen about the high costs of weight loss drugs Ozempic and Wegovy in the U.S. compared to other countries, seeking explanations for the disparity. These drugs have become popular among diabetic patients and those battling obesity, but access and affordability issues have been a concern for doctors and patients alike. The hearing, which included Sen. Bernie Sanders, aimed to address the challenges faced by individuals trying to obtain these medications.
Full Article
Loading PerspectiveSplit analysis...
